Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector‐based COVID‐19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al
| Autor: | Fredrik Kahn, Lars Björck, Oongh Shannon |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19) Platelet dysfunction Streptococcus pyogenes thrombocytopenia Letter to the Editors Viral vector Brain Ischemia Bacterial Proteins Heparin-induced thrombocytopenia vaccine Medicine Humans Platelet activation Letters to the Editor Acute ischemic stroke Letter to the Editor Ischemic Stroke business.industry SARS-CoV-2 IdeS Vaccination COVID-19 Hematology medicine.disease platelet factor 4 Stroke Immunology drug‐related side effects and adverse reactions business Platelet factor 4 |
| Zdroj: | Journal of Thrombosis and Haemostasis |
| ISSN: | 1538-7836 1538-7933 |
| Popis: | We acknowledge the commentary of Gruel et al. on our recent letter [1] and are pleased that the authors agree that IdeS may be a potential treatment option for the rare but potentially severe IgG-mediated platelet activation observed in complications to vaccination with ChAdOx1 nCoV-19. It is apparent that our respective but distinct expertise with regard to IdeS has led us to develop this hypothesis in parallel. As we clearly cited in our original letter these authors have previously contributed important evidence that IdeS may be beneficial in treating IgG-mediated platelet dysfunction in a mouse model of heparin induced thrombocytopenia [2]. The intention with our letter was to provide more background to IdeS and insight into the unique properties of IdeS that make it suitable for treating many manifestations of IgG-mediated human disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text